The present invention relates to tricyclic heterocycles of Formula (I): ##STR00001##
which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

The present invention relates to tricyclic heterocycles of Formula (I): ##STR00001##
which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

The present invention relates to macrocyclic indole derivatives of general formula (I) ##STR00001##
in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

The present invention relates to macrocyclic indole derivatives of general formula (I) ##STR00001##
in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.

Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.

A light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an interlayer located between the first electrode and the second electrode and including an emission layer, wherein the first electrode includes an inorganic material, the inorganic material includes a metal oxide having, as a main component, at least one metal selected from W, Mo, Ga, Ni, Cu, Zn, and Ti, the interlayer further includes a hole transport region located between the first electrode and the emission layer, the hole transport region includes a hole transport layer, and the hole transport layer includes at least one condensed cyclic compound represented by Formula 1:

##STR00001##

A light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an interlayer located between the first electrode and the second electrode and including an emission layer, wherein the first electrode includes an inorganic material, the inorganic material includes a metal oxide having, as a main component, at least one metal selected from W, Mo, Ga, Ni, Cu, Zn, and Ti, the interlayer further includes a hole transport region located between the first electrode and the emission layer, the hole transport region includes a hole transport layer, and the hole transport layer includes at least one condensed cyclic compound represented by Formula 1:

##STR00001##

An organic electroluminescence device includes: an anode; a cathode opposite the anode; and an organic layer interposed between the anode and the cathode, in which the organic layer includes: an emitting layer; and a first electron transporting layer and a second electron transporting layer which are provided on a side of the emitting layer near the cathode. The first electron transporting layer includes a compound represented by a formula (1) below, and the second electron transporting layer includes a compound represented by a formula (2) below.

##STR00001##

An organic electroluminescence device includes: an anode; a cathode opposite the anode; and an organic layer interposed between the anode and the cathode, in which the organic layer includes: an emitting layer; and a first electron transporting layer and a second electron transporting layer which are provided on a side of the emitting layer near the cathode. The first electron transporting layer includes a compound represented by a formula (1) below, and the second electron transporting layer includes a compound represented by a formula (2) below.

##STR00001##